Iclusig and Bone marrow failure - a phase IV clinical study of FDA data

Summary:

Bone marrow failure is reported as a side effect among people who take Iclusig (ponatinib hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Blincyto, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Bone marrow failure when taking Iclusig. It is created by eHealthMe based on reports of 6,108 people who have side effects when taking Iclusig from the FDA, and is updated regularly.

What is Iclusig?

Iclusig has active ingredients of ponatinib hydrochloride. eHealthMe is studying from 6,109 Iclusig users. Check the latest studies of Iclusig.

What is Bone marrow failure?

Bone marrow failure is found to be associated with 1,008 drugs and 1,438 conditions by eHealthMe. Check the latest studies of Bone marrow failure.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

6,108 people reported to have side effects when taking Iclusig.
Among them, 33 people (0.54%) have Bone marrow failure.

Could Iclusig cause Bone marrow failure?

Among these 33 people:

How long have people been on Iclusig when they have Bone marrow failure? *

What is the gender of people who have Bone marrow failure when taking Iclusig? *

female: 52 %
male: 48 %

What is the age of people who have Bone marrow failure when taking Iclusig? *

What are other drugs people take besides Iclusig? *

What are other side effects people have besides Bone marrow failure? *

Thrombocytopenia (decrease of platelets in blood): 7 people, 21.21%
Fever: 5 people, 15.15%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 5 people, 15.15%
Cough: 5 people, 15.15%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 5 people, 15.15%
Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 4 people, 12.12%
Headache (pain in head): 4 people, 12.12%
Lipase Increased: 4 people, 12.12%
Joint Pain: 3 people, 9.09%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 3 people, 9.09%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 13 people, 39.39%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 11 people, 33.33%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 4 people, 12.12%
Nausea And Vomiting: 3 people, 9.09%
Nausea (feeling of having an urge to vomit): 3 people, 9.09%
Depression: 2 people, 6.06%
Stress And Anxiety: 2 people, 6.06%
Acute Myeloid Leukaemia (In Remission): 2 people, 6.06%
Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 2 people, 6.06%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Iclusig and have Bone marrow failure?

- Check whether Bone marrow failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Iclusig:

Iclusig (6,109 reports)

Browse all side effects of Iclusig:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone marrow failure:

Bone marrow failure (1,008 drugs)

Browse all the conditions that are associated with Bone marrow failure:

Bone marrow failure (1,438 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ponatinib hydrochloride (the active ingredients of Iclusig) and Iclusig (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.